Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in cash is fair to Cerevel shareholders.
Halper Sadeh encourages Cerevel shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
The investigation concerns whether Cerevel and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Cerevel shareholders; (2) determine whether AbbVie is underpaying for Cerevel; and (3) disclose all material information necessary for Cerevel shareholders to adequately assess and value the merger consideration. On behalf of Cerevel shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh encourages Cerevel shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206978869/en/
